Pharmaceutical Company Releases Statement on Director Nominations

Friday 21st of March 2025 21:54:16

ATEA Pharmaceuticals Issues Statement Regarding Director Nominations

Benzinga Staff

ATEA Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for rare and orphan diseases, issued a statement today regarding director nominations.

The company announced that its board of directors has nominated four highly qualified individuals for election at the upcoming annual meeting of shareholders. The nominees include Dr. John McNamara, Dr. Kathryn Zoon, Mr. Michael Kelly, and Mr. David Higgins.

According to the statement, Dr. McNamara has over 20 years of experience in the pharmaceutical industry, having served in various leadership roles at companies such as Pfizer and Merck. Dr. Zoon has a strong background in clinical research, having worked at companies such as Genentech and Biogen. Mr. Kelly has extensive experience in the biotechnology industry, having served as CEO of several companies, including one that was acquired by a major pharmaceutical company. Mr. Higgins has a strong background in finance, having served as CFO of several companies, including one that went public.

The company's board of directors believes that these nominees have the skills, experience, and passion to help drive the company's mission forward and make important decisions that will benefit the company and its shareholders.

The annual meeting of shareholders is scheduled to take place on [date] and will be held at [location]. The nominees will be voted on by shareholders, with the top four candidates being elected to the board of directors.

ATEA Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for rare and orphan diseases. The company's lead product candidate is an orally administered small molecule that is being developed for the treatment of a rare genetic disorder. ATEA Pharmaceuticals is headquartered in [location] and has a team of experienced professionals working to advance its pipeline of product candidates.